{"contentid": 488362, "importid": NaN, "name": "Asthma treatment fails Phase III test in COVID-19", "introduction": "Swiss pharmaceutical company Covis Pharma has announced negative top-line results from a 400 patient Phase III trial of ciclesonide in non-hospitalized people with COVID-19.", "content": "<p>Swiss pharmaceutical company Covis Pharma has announced negative top-line results from a 400 patient Phase III trial of ciclesonide in non-hospitalized people with COVID-19.</p>\n<p>The company has been testing the therapy as an option to treat symptoms of the disease, including cough, dyspnea, chills and fever.</p>\n<p>While the trial missed its primary endpoint of improvement in these symptoms, a relevant secondary efficacy endpoint did reach statistical significance, with a reduction in subsequent visits to the emergency room, compared with placebo.</p>\n<p>Covis, a Zug-based global specialty pharmaceutical company, markets therapeutic solutions for patients with life-threatening conditions and chronic illnesses.</p>\n<p>The firm offers the glucocorticoid in an inhalable format under the brand name Alvesco, for long-term treatment of asthma in certain people in the USA and Canada.</p>\n<p>Steering committee member Michael Blaiss said: &ldquo;We are disappointed the results were not more positive, although there was a trend toward earlier cough cessation in the ciclesonide group.&rdquo;</p>\n<p>He added: &ldquo;Further studies may want to look at whether this treatment may prevent or lessen post-acute COVID-19 syndrome.&rdquo;</p>\n<p>In 2017, Covis picked up US rights to Alvesco, for the treatment of asthma and allergic rhinitis, from Sunovion, a wholly-owned subsidiary of Sumitomo Dainippon Pharma (TYO: 4506).</p>", "date": "2021-04-15 16:56:00", "meta_title": NaN, "meta_keywords": "COVID-, Phase, company, treatment, trial, pharmaceutical, Covis, results, ciclesonide, people, fails, test, asthma, Swiss, announced, negative, top-line", "meta_description": "Swiss pharmaceutical company Covis Pharma has announced negative top-line results from a 400 patient Phase III trial of ciclesonide in non-hospitalized people w", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-15 16:37:48", "updated": "2021-04-15 16:57:42", "access": NaN, "url": "https://www.thepharmaletter.com/article/asthma-treatment-fails-phase-iii-test-in-covid-19", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "vials_dugs_biologic_report_test_big.jpg", "image2id": "vials_dugs_biologic_report_test_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Anti-virals", "topic_tag": "Coronavirus, Drug Trial, Focus On, Research", "geography_tag": "Switzerland", "company_tag": "Covis Pharma", "drug_tag": "Alvesco, Ciclesonide Inhalation Aerosol", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-15 16:56:00"}